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N-acylphosphatidylethanolamines (NAPEs) are a rel-
atively abundant group of plasma lipids of unknown
physiological significance. Here, we show that
NAPEs are secreted into circulation from the small in-
testine in response to ingested fat and that systemic
administration of the most abundant circulating
NAPE, at physiologic doses, decreases food intake
in rats without causing conditioned taste aversion.
Furthermore, 14C-radiolabeled NAPE enters the brain
and is particularly concentrated in the hypothalamus,
and intracerebroventricular infusions of nanomolar
amounts of NAPE reduce food intake, collectively
suggesting that its effects may be mediated through
direct interactions with the central nervous system.
Finally, chronic NAPE infusion results in a reduction
of both food intake and body weight, suggesting
that NAPE and long-acting NAPE analogs may be
novel therapeutic targets for the treatment of obesity.
INTRODUCTION
Under normal conditions, appetite is regulated largely by the gut-
brain-adipocyte axis, an intricate circuit that balances energy
intake with energy expenditure to promote the maintenance of
energy reserves (Abizaid et al., 2006; Morton et al., 2006).
Hormones, nutrients and vagal afferents interact with targets in
the brainstem, hypothalamus, andmidbrain tomodify the activity
of neuronal populations that regulate food intake and energy
expenditure in both short- and long-term contexts (Cone et al.,
2001). Due to its fenestrated capillaries, the hypothalamic
arcuate nucleus (ARC) is well-suited to detect endocrine and
nutrient factors that regulate food intake (Fry and Ferguson,
2007). Orexigenic NPY and anorexigenic POMC ARC neurons
respond by communicating with second-order regulatoryneurons in the paraventricular nucleus (PVN) and lateral hypo-
thalamus (LH) to mediate the appropriate feeding behavior
(Schwartz et al., 2000).
In addition to integrating the effects of leptin, ghrelin, insulin,
and gastrointestinal peptides including CCK, PYY3-36, and
GLP-1, cells of the ARC regulate food intake by directly sensing
nutrients (Obici et al., 2002; Abizaid et al., 2006; Coll et al., 2007).
Peripheral or central infusions of glucose suppress food intake,
and disruption of glucose transport or its intracellular metabo-
lism elicit hyperphagia in experimental animals (Miselis and
Epstein, 1975; Wolfgang et al., 2007). Similarly, intracerebroven-
tricular (ICV) administration of L-leucine (Cota et al., 2006)
reduces food intake in rodents, suggesting that the central
nervous system (CNS) can sense short-term glucose and amino
acid availability independently of hormones secreted by the
gastrointestinal tract.
Neuronal sensing of fatty acids (FAs) has also been implicated
in the regulation of feeding behavior by studies demonstrating
that food intake can be reduced through inhibition of fatty acid
synthase (Loftus et al., 2000) or intrathecal oleic acid infusion
(Obici et al., 2002). However, in contrast to plasma concentra-
tions of glucose and amino acids, which increase after meals,
concentrations of plasma FAs typically decrease with feeding
and rise with fasting, contrary to what is expected of a negative
regulator of appetite (Dole, 1956). Furthermore, intravenous
infusions of lipid do not affect food intake, and thus it remains
unclear how either circulating triglyceride (TG) or FAs signal lipid
surfeit to the CNS under physiological conditions (Little et al.,
2007).
Given that other types of macronutrients communicate di-
rectly with cells in the hypothalamus, we hypothesized that
food intake could be modified by circulating nutrient signals
reflective of meal fat content. To examine this hypothesis, we
undertook a screen of lipid derivatives that increased in plasma
after high-fat feeding using liquid chromatography tandemmass
spectrometry (LC/MS/MS). Among these increased metabolites
was a class of phospholipids, the N-acylphosphatidylethanol-
amines (NAPEs), of previously unknown physiologic function inCell 135, 813–824, November 28, 2008 ª2008 Elsevier Inc. 813
plasma, whose hydrolysis products, the N-acylethanolamines,
have been implicated in the peripheral control of food intake
(Rodriguez de Fonseca et al., 2001; Fu et al., 2003). We found
that intraperitoneal and intravenous injection of the most abun-
dant plasma NAPE, at physiologic doses, reduced food intake.
RESULTS
Fat Feeding Increases NAPE Levels in Lymph
and Plasma
When fasted rats were fed a high-fat diet, we observed a 60% in-
crease in total plasma NAPE concentrations (Figure 1A). In order
to confirm that dietary lipids were responsible for this increase,
we subjected rats to intraduodenal infusions of lipid (Liposyn
II), a glucose polymer (dextrin), or protein (casein) and monitored
NAPE changes in lymph. Within 60 min of initiating the lipid infu-
sion, we found that lymph NAPE increased by more than 50%
and remained elevated for the duration of the 6 hr experiment
(Figures 1B and 1C). In contrast, there were no significant
increases in lymph NAPE concentrations after dextrin or protein
administration in an identical infusion protocol (Figure 1B).
We next examined the effects of lipid or dextrin infusion on
NAPE concentrations in plasma. Consistent with the results
from the lymph studies, we found that lipid, but not dextrin,
infusion increased plasma NAPE levels by approximately 40%
Figure 1. Regulation of NAPE Levels in Rat
Plasma, Lymph and Small Intestine by Fat
Feeding and Intraduodenal Lipid Infusion
(A) High-fat chow feeding increases total plasma
NAPE (p < 0.025) at 4 hr relative to fasting condi-
tions (n = 8 per group).
(B) Time course of intraduodenal lipid (solid
squares), dextrin (filled triangles), or protein
(open circles, dashed line) infusions’ effects on
relative lymph NAPE concentration (p < 0.0025)
(n = 4–8 per group).
(C) Intraduodenal infusion of lipid significantly
increases absolute NAPE concentration in lymph
4 hr after the start of the experiment (p < 0.02)
(n = 7–8 per group).
(D) Intraduodenal infusion of lipid, but not dextrin,
increases plasma NAPE concentration (p < 0.02)
4 hr after the start of the experiment (n = 4 per
group).
(E) N-acyl species profile of plasma NAPE at 4 hr
after the start of the lipid infusion (solid bars)
compared with fasting levels in the same animals
(open bars) (n = 4 per group).
(F) High-fat feeding significantly increases NAPE
content in the small intestine relative to fasting
(p < 0.05) (n = 4 per group).
All data are expressed as mean ± SEM.
within 1 hr of the start of the lipid infusion
and maintained them at elevated levels
for the duration of the experiment (Fig-
ure 1D). In order to determine which
acyl species of NAPE increased after lipid
infusion, we analyzed plasma samples
from fasted and lipid-infused rats with LC/MS/MS. We found
that 16:0, 18:0, 18:1, and 18:2 NAPEs all increased by
more than 50% in plasma, whereas levels of the endocannabi-
noid precursor 20:4 NAPE remained unchanged (Figure 1E).
Because C16:0 is the most abundant circulating NAPE and the
most increased by fat infusion, it was chosen for subsequent
studies.
Fat Feeding Increases NAPE Content in the Small
Intestine
Since the fatty acid components of NAPE that appeared in the
plasma and lymph after lipid infusion were similar to the fatty
acid composition of the infused lipid, we reasoned that the
plasma and lymphatic NAPE was derived from the infused lipid
and synthesized in the gut. In order to test this hypothesis and
determine where in the gastrointestinal tract NAPE might be
synthesized, we examined NAPE content in the stomach, small
intestine, and large intestine in rats that had either been fasted
or refed with a high-fat diet. We found that NAPE content
increased in the small intestine after fat feeding (Figure 1F)
but did not change in the stomach or colon (Figure S1 available
online). These data are consistent with previous studies demon-
strating NAPE synthesis in small intestinal gut segments with
feeding (Petersen et al., 2006; Fu et al., 2007).814 Cell 135, 813–824, November 28, 2008 ª2008 Elsevier Inc.
Figure 2. C16:0 NAPE Treatment Sup-
presses Food Intake Dose Dependently
without Causing Conditioned Taste Aver-
sion
(A) Systemic (i.p) NAPE administration significantly
reduces the rate of food intake in a dose-
dependent manner at 200 mg/kg, 500 mg/kg,
and 1000 mg/kg (p < 0.01) in free-feeding mice
(n = 4–14 per group).
(B) Systemic (i.p) NAPE administration reduces
overnight cumulative food intake dose-depen-
dently in free-feeding mice (n = 4–11 per group).
(C) Treatment with 100 mg/kg C16:0 NAPE (i.p.)
significantly reduces overnight food intake in ad
libitum-fed rats at t = 3 hr (p < 0.03) and overnight
t = 13 (p < 0.004) (n = 6 per group).
(D) Treatment with 100 mg/kg C16:0 NAPE (i.p.),
a dose sufficient to reduce overnight food intake,
does not produce conditioned taste aversion in
rats, in contrast to 100mg/kg LiCl. Open bars indi-
cate the amount of saccharin solution consumed
when presented to 24 hr water-deprived, naive
rats, and filled bars show the amount of saccharin
solution consumed in 24 hr water deprived rats
trained to associate the sweet taste with saline,
C16:0 NAPE, or LiCl (n = 6 per group).
(E) Total plasma NAPE time course in fasted
rats injected with 100 mg/kg C16:0 NAPE at t = 0
(n = 5–9 per time point).
(F) Total plasma NAPE time course in fasted rats
given an intraduodenal infusion of lipid (Liposyn
II) at t = 0 (n = 4 per group).
(G) C16:0 NAPE (500 mg/kg) dramatically sup-
presses overnight food intake in ad libitum-fed
ob/ob mice at t = 3 (p < 0.002) and t = 12 (p <
0.0001) (n = 4 per group).
(H) C16:0 NAPE (500mg/kg) suppresses overnight
food intake in fasted CB1/ mice (p < 0.0005)
(n = 5 per group).
All data are expressed as mean ± SEM.The Most Abundant Plasma NAPE Reduces Food Intake
in Rats and Mice without Causing Taste Aversion
We next examined whether exogenous administration of NAPE
could alter food intake. We injected rats and mice intraperitone-
ally with varying doses of C16:0 NAPE andmonitored food intake
and activity in metabolic cages. We found that NAPE treatment
reduced food intake in a dose-dependent manner, whereas
an isovolumetric dose of lipid had no such effect (Figure 2A). Fur-
thermore, food intake was almost completely suppressed at the
highest dose of NAPE, and its anorexigenic effects at this dose
persist for 12 hr (Figure 2B).
In rats, C16:0 NAPE (100 mg/kg i.p.) given immediately before
the onset of the dark cycle, the interval during which rats
consume the bulk of their daily calories, significantly reduced
food intake (Figure 2C). Importantly, this dose of NAPE, as well
as a higher dose of NAPE (250 mg/kg i.p.) and intracerebroven-
tricular infusion of NAPE (80 nmol) did not cause conditionedtaste aversion (CTA), unlike the noxious agent lithium chloride
(Figure 2D and Figure S2).
Fat Feeding and 100 mg/kg NAPE Treatment Produce
Similar Increases in Plasma NAPE Levels
Because many compounds of endogenous origin affect feeding
behavior when administered in sufficient quantities, we sought to
test the physiological significance of NAPE as a regulator of food
intake. Measurement and comparison of plasma NAPE levels af-
ter 100mg/kg i.p. injection of C16:0 NAPE or intraduodenal bolus
of Liposyn II at t = 0 (Figures 2E and 2F) indicate that both the
absolute increase in circulating NAPE and the time course of
that increase are similar between the lipid-fed and NAPE-
injected groups. Changes observed in mice treated with NAPE
(100 mg/kg i.p.) were similar, increasing from 3.8 ± 0.3 mM at
baseline to a peak of 12 ± 2.6 mM at 3 hr after injection (n = 5 per
group, data not shown).Cell 135, 813–824, November 28, 2008 ª2008 Elsevier Inc. 815
ob/ob Mice are Hypersensitive to Exogenous NAPE
Administration
To investigate the possibility that the actions of NAPE may
exert its effects through leptin signaling, we tested its effects
on leptin-deficient ob/ob mice. Surprisingly, we found that the
ob/obmice were actually more sensitive than wild-type controls
to the satiating effects of exogenously administered NAPE
(Figure 2G).
CB1/ Mice Respond Normally to Exogenous NAPE
Administration
Considering NAPE’s structural similarity to identified endoge-
nous CB1 agonists, we also examined whether the effects of
NAPE require the CB1 receptor by studying NAPE treatment in
CB1/ mice. We found that NAPE treatment was still effective
in suppressing overnight food intake inCB1/mice, suggesting
that NAPE reduces food intake independently of the CB1 recep-
tor (Figure 2H).
Central NAPE Administration Reduces Food Intake
Because the vast majority of appetite-regulatory factors have
targets in the CNS, we tested the hypothesis that NAPE effects
on food intake are centrally mediated. To do this, we injected
C16:0 NAPE (80 nmol) into the lateral ventricle of chronically
cannulated (ICV) mice and recorded overnight food intake rela-
tive to ICV lipid-treated (Liposyn II) control mice in metabolic
cages. We found that ICV injection of C16:0 NAPE reduced
food intake by 56% at 12 hr relative to lipid-treated animals
(Figure 3A). In a second control experiment, we found that
central infusion of an isomolar quantity of another phospholipid,
dioleoylphosphatidylethanolamine (DOPE), had no effect on
food intake (Figure 3B).
NAPE Reduces Food Intake in Vagotomized Rats
Although the above investigation indicated central activity, we
sought to exclude the possibility that vagal afferents were
responsible for NAPE-induced hypophagia by examining the
effects of systemic NAPE injection in rats that were either
subjected to a bilateral subdiaphragmatic vagotomy or a sham
procedure in which the vagus nerve was exposed but not sev-
ered. When given identical doses of C16:0 NAPE (100 mg/kg),
the two groups were found to have similar NAPE-induced reduc-
tions in food intake (Figure 3C, shamgroup, data not shown). The
surgical procedure itself caused no differences in long term food
intake or body weight (Figure S3).
14C-NAPE Crosses the Blood-Brain Barrier
and Is Concentrated in the Hypothalamus
To examine whether plasma C16:0 NAPE is able to enter the
central nervous system, we infused catheterized rats with a
bolus of 14C-NAPE and measured 14C counts in the brain and
hypothalamus 4 hr after treatment. After 14C-NAPE infusions, we
found significant increases in 14C counts in the brain and more
importantly a more than 5-fold increase in 14C counts in the
hypothalamus. This suggests that at minimum, the N-acyletha-
nolamine (NAE) head group of NAPE is capable of entering the
CNS from peripheral circulation and that it preferentially
accumulates in the hypothalamus (Figure 3D).816 Cell 135, 813–824, November 28, 2008 ª2008 Elsevier Inc.Central Administration of Palmitoylethanolamide Does
Not Affect Food Intake
Because NAPEs are precursors of NAEs, which have been
shown to influence food intake, we also infused the hydrolysis
product of C16:0 NAPE, palmitoylethanolamide (PEA) directly
into the lateral ventricle of cannulated mice. In contrast to
NAPE, PEA did not suppress food intake overnight when admin-
istered in this manner (Figure 3E). Moreover, treatment of mice
(i.p.) with an inhibitor of NAE hydrolysis, URB579, at a dose
sufficient to quadruple NAE concentrations in the CNS, did not
affect overnight food intake in fasted mice (Figure 3F). Taken
together, these data are consistent with previous studies dem-
onstrating no effect of intrathecal administration of the NAE
oleoylethanolamide (OEA) on food intake (Rodriguez de Fonseca
et al., 2001).
Central and Peripheral NAPE Administration Reduces
Voluntary Locomotor Activity
In addition to the dose-dependent effect of NAPE to reduce food
intake, we also found that NAPE administration caused a dose-
dependent reduction in activity (Figure 4A) reminiscent of the ro-
dent behavioral satiety sequence characterized by postprandial
grooming and rest (Halford et al., 1998). To exclude the possibil-
ity that this reduction in activity may have physically prevented
animals from gaining access to food, we examined the effect
of NAPE treatment on mouse performance on an accelerating
rotarod, a well-validated measure of motor performance (Carter
et al., 1999). Pretrainedmice treatedwith the highest tested dose
of C16:0 NAPE performed as well as mice that received vehicle,
suggesting that the reduction in movement elicited by NAPE
treatment is voluntary (Figure 4B). We next examined whether
ICV administration of C16:0 NAPE in mice had similar effects
on locomotor activity as did peripheral treatments, and we found
that very small quantities of ICV administered NAPE were suffi-
cient to reproduce the behavioral effects obtained from much
larger doses of NAPE given by intraperitoneal injection
(Figure 4C).
NAPE Treatment Reduces Fasting-Induced Increases
in NPY Neuron cFOS Expression
Neuropeptide Y (NPY) stimulates feeding and increases behav-
ioral arousal (Stanley and Leibowitz, 1985; Sahu et al., 1988;
Kalra et al., 1999). Because NAPE treatment decreased food
intake and activity, we hypothesized that its effects might beme-
diated by NPY neurons in the hypothalamic ARC. We tested this
hypothesis by quantifying immediate early gene cFOS expres-
sion in fasted transgenic mice expressing green fluorescent pro-
tein (GFP) in NPY neurons with and without NAPE treatment.
Fasting increases NPY activity in the ARC, compared to the
fed state, as reflected by a 4-fold increase in cFOS expression
in these cells (Figures 5A, 5B, and 5G). With intraperitoneal
NAPE treatment, however, cFOS activity in NPY neurons was
suppressed by 64%, to a level comparable to that observed in
the free-feeding ARC (Figures 5C, 5G, and 5H). In addition, we
found that the canonical fasting-induced cFOS expression
throughout the ARC was decreased by NAPE treatment, sug-
gesting that increases in systemic NAPE may also suppress
fasting-elicited transcriptional activity in other neural networks in
the hypothalamus (Figures 5D–5F and 5I).
NAPE Treatment Stimulates cFOS Expression
in the Paraventricular and Supraoptic Nuclei
of the Hypothalamus
cFOS staining performed in brain slices obtained from other
areas demonstrated rapid and dramatic activation of neurons
in the PVN (Figures 5J–5L) and supraoptic nucleus (SO)
(Figure S4) in response to NAPE treatment relative to fasting.
Chronic High-Fat FeedingEliminates Postprandial NAPE
Secretion but Not Sensitivity to Exogenous NAPE
In order to examine whether alterations in NAPE production, or
perturbed NAPE signaling, may play a role in diet induced
obesity, we fed rats either a high-fat diet (HFD) or a regular
Figure 3. C16:0 NAPE Treatment Suppresses Food Intake by a Central Mechanism
(A) Central (i.c.v.) administration of C16:0 NAPE (80 nmol) significantly (p < 0.0001) reduces overnight food intake in mice relative to lipid control (Liposyn II)
(n = 6–7 per group).
(B) i.c.v. administration of 80 nmol dioleoylphosphatidylethanolamine (DOPE), a phospholipid, to mice does not reduce food intake relative to lipid control
(Liposyn II) (n = 4 per group).
(C) C16:0 NAPE (100 mg/kg i.p.) reduces overnight food intake in vagotomized rats, indicating that its suppressive effects on food intake do not require intact
vagal afferents (p < 0.05) (n = 5–8 per group).
(D) Intravenous infusion of 2.5 mCi 14C NAPE significantly increases counts in the brain (p < 0.0001) and hypothalamus (p < 0.03) of treated animals relative to
controls at t = 4 (n = 5–6 per group).
(E) Central administration of PEA, the C16:0 NAPE hydrolysis product (100 nmol), does not affect overnight food intake in mice (n = 6–7 per group).
(F) Systemic pretreatment with URB597 (0.3 mg/kg), an inhibitor of central NAE degradation, which increases brain NAE concentrations, does not affect food
intake in fasted mice (n = 4 per group).
All data are expressed as mean ± SEM.Cell 135, 813–824, November 28, 2008 ª2008 Elsevier Inc. 817
chow (RC) diet for 1 month, implanted jugular venous catheters,
allowed for postoperative recovery, and then measured NAPE
secretion in plasma after a high-fat meal after an overnight
fast. As we have shown, animals maintained on RC showed
a marked increase in plasma NAPE concentrations after the
high-fat meal.
Surprisingly, animals fed with HFD for 35 days prior to the
experiment, although exhibiting high to normal NAPE concentra-
tions at baseline, were unable to induce secretion postprandially
and even showed a significant reduction in circulating NAPE
during the postmeal interval (Figure 6A). Despite this derange-
ment in NAPE synthesis and/or secretion after fat feeding, the
chronically high fat-fed animals remained responsive to the
anorectic effects of C16:0 NAPE in separate feeding studies
(Figure 6B).
Continuous Low-Dose NAPE Infusion Reduces Food
Intake and Body Weight
Finally, we examined whether chronic C16:0 NAPE administra-
tion would have an effect on energy balance and food intake in
a multiday experiment. We infused vehicle or C16:0 NAPE
(0.07 mg/kg/min) intravenously in chronically catheterized free-
ranging rats while recording daily food intake and body weight.
After 5 days of treatment, we found that cumulative food intake
in the NAPE-treated rats was reduced by approximately 30%
Figure 4. Central and Peripheral NAPE Treatment Reduces Sponta-
neous Activity
C16:0 NAPE administration (i.p.) reduces locomotor activity without causing
motor deficits, and central administration of a small quantity of i.c.v. NAPE is
sufficient to reproduce this effect.
(A) Systemic C16:0 NAPE administration produces a dose-dependent reduc-
tion in motor activity relative to lipid control at 100 mg/kg (p < 0.01), 500 mg/kg
(p < 0.001), and 1000 mg/kg (p < 0.001) (n = 4–12 per group).
(B) Systemic (i.p.) NAPE administration (1000mg/kg) does not affect time to fall
from the accelerating rotarod, a test of motor coordination and ability to
respond to a motor challenge in pretrained mice (n = 5 per group).
(C) Central administration (i.c.v.) of C16:0 NAPE, 80 nmol, or 0.25% of the
maximum dose (1000 mg/kg) given peripherally causes a similar reduction in
locomotor activity (p < 0.0001) (n = 3 per group).
All data are expressed as mean ± SEM.818 Cell 135, 813–824, November 28, 2008 ª2008 Elsevier Inc.compared to the vehicle infused rats (Figures 7A and 7C) and
that the consequence of this hypophagia was significant weight
loss in the NAPE group without any other behavioral changes
(Figure 7B).
DISCUSSION
Because dietary fat is the most obesity-promoting macronutri-
ent, it has been identified as an important causal factor in the
obesity epidemic (Donahoo et al., 2008). Therefore, understand-
ing the processes by which dietary fat intake is regulated
and how these mechanisms malfunction in our modern environ-
ment may lead to new therapeutic options for the treatment of
obesity. In this paper, we present data suggesting that circulat-
ing NAPEs may be involved in the physiologic regulation of
dietary fat intake.
In contrast to peptidemediators of satiety or satiation like CCK
and GLP-1 that are released by endocrine cells of the gastroin-
testinal tract in response to multiple types of ingested of macro-
nutrients (Little et al., 2007), we found that secretion of NAPEs
into plasma and lymph requires the consumption of dietary lipid.
Because NAPE levels are unchanged in the stomach and large
intestine with nutrient intake, and because studies using labeled
precursors have shown that intestinal tissues readily synthesize
NAPE (Rodriguez de Fonseca et al., 2001; Petersen et al., 2006),
these data suggest that the small intestine is themajor source for
the increase in lymph and plasma NAPEs seen under these
conditions of fat feeding.
When administered systemically to rats and mice, C16:0
NAPE reduced food intake in a dose-responsive fashion. Impor-
tantly, a 100 mg/kg i.p. dose of C16:0 NAPE caused significant
reduction in food intake while increasing plasma NAPE levels
to a similar extent as that observed after intraduodenal lipid
infusion. This suggests that the reduction in food intake at this
dose is physiologic and that NAPE generation and secretion
into circulation may be one means by which the gut conveys
information about lipid availability in the digestive tract to the
central nervous system, likely in concert with increased NAE
signaling in the small intestine (Fu et al., 2007). Furthermore,
our finding that NAPEs circulate in plasma at much higher
concentrations than NAEs (low mM versus low nM range) may
explain why many of the targets activated by NAEs, including
the anorexigenic G protein-coupled receptor GPR119, require
apparently supraphysiological concentrations of NAE ligand to
respond (Overton et al., 2006). If NAPEs can also activate these
receptors, then this apparent paradox might be resolved. It is
also important to note that at 100 mg/kg or 250 mg/kg, C16:0
NAPE did not cause conditioned taste aversion, a behavioral
response elicited in experimental animals by compounds that
cause nausea or general malaise, supporting the possibility
that NAPE is a physiologic regulator of food intake. However,
because intraperitoneal, but not intravenous, NAPE treatment
can produce transient, nonaversive postural changes in rats,
but not mice, during the immediate postinjection period, the lat-
ter mode of administration is preferable and most physiologic.
Regardless, both routes of administration had the same net
effect on food intake and energy balance.
Figure 5. Peripheral NAPE Treatment Antagonizes Fasting-Evoked cFOS Changes in the Hypothalamus
Systemic C16:0 NAPE treatment (1000 mg/kg i.p.) reduces fasting-induced activation of NPY neurons in the hypothalamic ARC of transgenic mice expressing
GFP in NPY neurons and increases cFOS expression in the hypothalamic PVN. cFOS is stained in red.
(A) cFOS-GFP colocalization in the arcuate nucleus of free-feeding mice is low, indicating few transcriptionally active NPY neurons (small scale bar, inset, 10 mm;
large scale bar, panel, 100 mm).
(B) Overnight fasting dramatically increases colocalization, indicating activated NPY neurons.
(C) C16:0 NAPE treatment of fasted animals results in reduction of NPY-GFP colocalization to fed levels.
(D) Diffuse expression of cFOS is low in the ARC of free-feeding animals.
(E) Overnight fasting also stimulates cFOS expression in GFP-negative cells throughout the ARC.
(F) C16:0 NAPE treatment markedly reduces cFOS expression in the ARC of fasted animals.
(G) Quantification of percent cFOS-GFP colocalization in the arcuate nucleus of all fasted, fed, and NAPE-treated animals (p < 0.001) (n = 4–5 per group).
(H) Quantification of NAPE-induced reductions in the number of cFOS-NPY positive neurons/0.1mm3 in the ARC relative to fasting (p < 0.0001) (n = 4–5 per group).
(I) Quantification of NAPE-induced reductions in the number of cFOS positive cells/0.1mm3 in the ARC relative to fasting (p < 0.0001) (n = 4–5 per group).
(J) Representative section at 20X stained for cFOS in a vehicle-treated animal shows low cFOS expression in the PVN.
(K) NAPE treatment significantly increases cFOS staining in the PVN.
(L) Quantification of percent cFOS induction in the PVN by 1000 mg/kg C16:0 NAPE in all animals (p < 0.008) (n = 4–5 per group).
All data are expressed as mean ± SEM.Cell 135, 813–824, November 28, 2008 ª2008 Elsevier Inc. 819
Figure 6. Chronic High-Fat Feeding Elimi-
nates Postprandial NAPE Secretion without
Altering Sensitivity to Its Anorexic Effects
(A) High-fat feeding significantly increases plasma
NAPE at 4 hr relative to fasting in rats maintained
on regular chow (open bar), but this effect is
absent in animals fed high-fat chow for 35 days
prior to the experiment (filled bar) (p < 0.008)
(n = 6–14 per group).
(B) Treatment with 100 mg/kg C16:0 NAPE pro-
duces similar reductions in food intake in animals
maintained on regular chow and animals fed for
35 days with high-fat chow (n = 6–8 per group).
All data are expressed as mean ± SEM.An unexpected result of this study was that ob/ob mice were
more sensitive than wild-type animals to the anorectic effects
of C16:0 NAPE. Although no definitive explanation for this effect
yet exists, one might speculate that leptin may be a permissive
signal for NAPE generation or that, similar to our chronically
high-fat fed rats, NAPE secretion in response to dietary lipid
may be blunted in these mice, thus augmenting their sensitivity
to exogenous C16:0 NAPE administration.
Because 20:4 NAPE is the precursor of the NAE anandamide
(AEA), a CB1 receptor agonist, we tested C16:0 NAPE in the
CB1/ mouse and found that its overnight food intake was re-
duced to a similar extent to that of wild-type mice treated with
an equivalent dose of NAPE, indicating that the anorectic effects
of NAPE are independent of the CB1 receptor. We cannot, how-
ever, exclude the possibility that CB-type signaling mediates
some of NAPE’s effects in light of the recent report that
GPR55, an orphan G protein-coupled receptor, is potently acti-
vated by both PEA, the hydrolysis product of C16:0 NAPE, and
D9-tetrahydrocannabinol (Ryberg et al., 2007). This potential
overlap with cannabinoid signaling raises interesting questions
about the possible involvement of NAPE, or NAPE metabolites,
in mediating the rewarding properties of dietary lipid. However,
neither direct infusion of PEA into the lateral ventricle nor the820 Cell 135, 813–824, November 28, 2008 ª2008 Elsevier Inc.pharmacologic elevation of all NAEs in the CNS by inhibition of
fatty acid amide hydrolase (FAAH), their catabolic enzyme,
affected food intake.
Several of our observations suggest that NAPE may reduce
food intake by direct interaction with uncharacterized targets in
the central nervous system. First, we found that C16:0 NAPE
infusion into the lateral ventricle of cannulated mice, at far lower
doses than used in the periphery (75 mg i.c.v. versus 100 to
1000 mg/kg i.p.), significantly reduced food intake relative to
i.c.v. injections of an isovolumetric bolus of Liposyn II or an
isomolar quantity of phosphatidylethanolamine. Second, elimi-
nation of nervous afferents to the brain from the gastrointestinal
tract by subdiaphragmatic vagotomy did not block the anorectic
effects of NAPE. And, finally, intravenous 14C-labeled C16:0
NAPE entered the brain and preferentially accumulated in the
hypothalamus.
In the ARC, we found that NAPE treatment reduced fasting-
dependent induction of the immediate-early gene cFOS, which
is commonly used as an indirect marker of neuronal activity. A
simple interpretation of these data is that NAPE treatment blocks
the stimulatory effect that fasting has on cFOS protein produc-
tion in the hypothalamus and that the observed decrease in
these experiments is the product of normal degradation.Figure 7. Continuous NAPE Infusion
Reduces Food Intake and Body Weight
Chronic intravenous infusion of C16:0 NAPE
(100 mg/kg-day or 0.07 mg/kg-min) significantly
reduces cumulative food intake and body weight
in ad libitum-fed rats.
(A) Time course of cumulative food intake in
rats treated either with vehicle solution or
0.07 mg/kg-min over 5 days (p < 0.0001) (n =
7–15 per group).
(B) Comparison of weight change of vehicle
treated controls and NAPE treated animals after
5 days of infusion (p < 0.0001) (n = 7–15 per group).
(C) Cumulative food intake after 5 days in vehicle-
treated controls and NAPE-treated animals after
5 days of infusion (p < 0.0001) (n = 7–15 per group).
All data are expressed as mean ± SEM.
However, these experiments do not provide information regard-
ing the precise transcriptional or electrical changes brought
about by NAPE, only that it antagonizes fasting-regulated induc-
tion of cFOS in NPY neurons and others in the ARC, producing
a distribution of cFOS protein much more similar to what is ob-
served in the fed brain. If cFOS expression in this case correlates
well with neuronal activity, then the reduction in electrical firing of
these cell populations may contribute to NAPE-mediated
hypophagia. Future electrophysiology experiments in mice that
express GFP in different neuronal subpopulations will help to
better characterize the cell types and brain regions responsible
for NAPE-elicited changes in behavior.
In opposition to its effects in the ARC, C16:0 NAPE treatment
stimulates cFOS protein expression in the hypothalamic PVN
and SO nuclei. The anorexigenic peptides CCK-8 (Kobelt et al.,
2005), leptin (Emond et al., 2001), and GLP-1 (Turton et al.,
1996; Rowland et al., 1997) also stimulate cFOS expression in
the PVN, and lesions to this nucleus produce marked hyperpha-
gia, indicating that it may be an important appetite-regulatory
region. The induction of cFOS in the PVN and SO by C16:0
NAPE is of further interest because single copy mutations of
the transcription factor single-minded 1 (SIM1) in mice cause
significant cell loss in these regions, obesity, and an impaired
ability to sense changes in dietary fat content (Holder et al.,
2000; Holder et al., 2004).
A curious property of C16:0 NAPE is its ability to reduce loco-
motor activity in rodents when given systemically or centrally.
Because NAPE treatment did not cause taste aversion or deficits
in rotarod performance, these data suggest that it may play
a physiologic role in mediating the lassitude typically observed
in rodents during the postabsorptive state. There is precedent
for interactions between circulating regulators of appetite
and the motor circuits in the brain; acute knockdown of the
leptin receptor in the ventral tegmental area (VTA) has been
shown to increase locomotor activity in rodents (Hommel et al.,
2006).
A particularly noteworthy finding of this study was that expo-
sure to high-fat diet for 35 days eliminated the normal postpran-
dial increases in circulating NAPE observed in response to fat
feeding. These data suggest that derangements in NAPE secre-
tion associated with chronic high-fat feeding may contribute to
the pathogenesis of diet-induced obesity precipitated by over-
exposure to triglyceride-rich foods. Also, in contrast to leptin,
whose anorexigenic properties are rapidly diminished by obe-
sity, C16:0 NAPEwas able to still suppress food intake in animals
chronically fed a high-fat diet for 35 days.
To characterize the effects of prolonged NAPE treatment on
overall energy balance, we chronically infused (i.v.) rats with
a low dose of C16:0 NAPE for 5 days, and we observed signifi-
cant reductions in food intake and bodyweight relative to vehicle
treated rats without adverse effects. These results suggest that
chronic C16:0 NAPE treatment is capable of generating a state
of negative energy balance over multiple days and merits lon-
ger-term studies in rodents and nonhuman primates to examine
its potential for treatment and prevention of diet-induced
obesity. In conclusion, these data support the hypothesis that
circulating NAPEs, synthesized in the small intestine from in-
gested fat, may be part of an important physiologic negativefeedback loop that serves to reduce food intake and arousal
after a fat-containing meal.
EXPERIMENTAL PROCEDURES
Animals
For all studies in mice, animals of the C57BL6 strain (20–25 g, Charles River,
Boston, MA) were maintained on a standard light-dark cycle (12 hr of light
followed by 12 hr of darkness) in the Yale Animal Resources Center (YARC)
and unless otherwise indicated had ad libitum access to food pellets (Harlan
2018S, Indianapolis IN) and water. Similarly, Sprague Dawley rats were
purchased from Charles River and maintained on a 12-12 light-dark cycle in
the YARC with free food (Harlan 2018S, Indianapolis IN) access unless other-
wise indicated. All animal experiments received prior approval from the Yale
University and the University of Cincinnati Institutional Animal Care and Use
Committees.
LC/MS/MS Analyses
All LC/MS/MSmethod development and analyseswere performed on a bench-
top Applied Biosystems Instrumentation (ABI) 4000 QTRAP LC/MS/MS
system (Foster City, CA), equippedwith a Dionex Ultimate capillary liquid chro-
matography (Sunnyvale, CA) and a DionexFamos autosampler (Sunnyvale,
CA) together with a PEAK scientific gas generator (Bedford, MA). Both electro-
spray ionization (ESI) and atmospheric pressure chemical ionization (APCI)
sources were tested with positive- and negative-ion detection. Positive-ion
APCI source was found as the most sensitive for both qualitative characteriza-
tion and quantitative measurements of the NAE, NAPE, and PE metabolites;
thus, it was chosen for all method development and applications herein. The
autosample temperature was set at 4C–8C to minimize the possible
degradation of the extracted lipid samples, and aliquots of 5 ml sample solution
were injected for each analysis. The tuning and calibration of the mass
spectroscopy was performed at unit mass resolution in both positive- and
negative-ion modes with a polypropylene glycol (PPG) standard solution.
The mass spectra were interpreted and quantified with Analyst software
(version 1.4.1).
High-Fat Diet Screening Study
Eight rats equipped with jugular vein catheters were fasted 24 hr overnight and
blood (300 ml) was collected in the fasted state and at 1.5 and 4 hr after refeed-
ing with high-fat chow (59% of calories from fat, AIN-93G, Dyets, Bethlehem,
PA). The extracted plasma was analyzed for lipid metabolites, including NAPE
and NAE, whose extraction is described in the Supplemental Data.
Metabolic Cage Experiments
For food intake studies (i.p. treatment), mice were placed in individual
cages and allowed to acclimate to the calorimetric apparatus. This
comprehensive animal metabolic monitoring system (CLAMS; Columbus
Instruments) was used to evaluate activity, food consumption, and energy
expenditure.
Immediately prior to lights out at 7:30 PM, ad libitum-fed animals (four
in each group/trial) were injected i.p. with lipid control (Liposyn II + 10%
Tween 80 or in some cases sterile saline + 10% Tween 80) or the indicated
dose of NAPE, at a concentration of 100 mg/kg, 200 mg/kg, 500 mg/kg, or
1000 mg/kg dissolved in the vehicle solution. Food intake was monitored by
the CLAMS system for at least the next 12 hr before the experiment was termi-
nated. Solutions were prepared by adding Tween 80 to NAPE, stirring, adding
the balance solution and sonicating for 30–60 s.
Taste Aversion Studies
In brief, three groups of rats (n = 6 per group) were accustomed to a paradigm
of serial water deprivation (24 hr) and re-presentation (30min) until water intake
over the presentation period was stable between test days. Once water intake
had stabilized, animals were allowed 30 min of access after 24 hr of water
deprivation to solutions containing 0.1% saccharin (Sigma, St. Louis, MO). Im-
mediately after removal of the novel flavor solution, animals were injected with
vehicle solution, 100 mg/kg or 75 mg/kg LiCl in vehicle solution, or 100 mg/kgCell 135, 813–824, November 28, 2008 ª2008 Elsevier Inc. 821
NAPE or 250 mg/kg NAPE in vehicle solution. After a period of recovery days
during which water intake stabilized in the deprivation-30 min presentation
model, animals were again presented with 0.1% saccharin solution after
24 hr of water deprivation, and their saccharin intake was recorded to test
for conditioned taste aversion. The experiment was adapted from Riley and
Freeman (2004). For the ICV taste aversion experiment, rats with lateral ventri-
cle cannulas (Taconic Farms, Germantown, NY) were infused with 2.5 ml of
NAPE solution (30 mg/ml) dissolved in vehicle solution.
Intracerebroventricular Infusion Food Intake Studies
Male mice (n = 11–12) were anesthetized with ketamine and xylazine anesthe-
sia and equipped with 33 gauge cannulas (Plastics One, Roanoke, VA, USA).
After an incision was carefully made in the scalp and the bregma was located,
a small hole was drilledwith a 25 gauge needle 1mm lateral and 0.5mmcaudal
to the bregma. The cannula was then secured with dental cement (Lang Dental
Mfg. Co., Inc. Wheeling, IL).
Upon recovery, ad libitum-fed cannulated mice were injected with the
indicated dose of NAPE in vehicle or vehicle alone (Liposyn II + 10% Tween
80 in 2.5 ml) immediately before lights out, and food intake was recorded
with the complete metabolic monitoring system described above. An identical
protocol was used for i.c.v. treatment with dioloeylphosphatidylethanolamine
(DOPE) and PEA.
URB597 Food Intake Studies
In these studies, 24 hr-fasted mice were injected with either vehicle (saline +
10%Tween 80) or 0.3mg/kg URB597 in vehicle, and food intake was recorded
overnight.
NPY-GFP and cFos Immunohistochemistry
For the fasting-induced cFOS and cFOS-NPY colocalization experiment, over-
night fasted mice were treated 1 hr prior to sacrifice with 1000 mg/kg NAPE (in
Liposyn II + 10% Tween 80) or lipid control (Liposyn II + 10% Tween 80). Upon
sacrifice mice, were subjected to intracardiac perfusion with a solution con-
taining 4% paraformaldehyde, 15% picric acid, and 0.1% glutaradlehyde,
and the dissected brains were postfixed overnight in an identical solution lack-
ing glutaraldehyde. After several rinse steps, the brains were cut in 50 mM
sections with a vibratome and washed in 0.1 M phosphate buffer (PB). After
treatment in 1% H2O2 for 12.5 min, the slices were washed for 30 min in PB
prior to incubation for an additional 12.5 min in a solution containing 20 ml/ml
Triton X-100/ml. After this step, slices were washed with PB for 30 min.
Next, slices were incubated overnight with a rabbit antibody generated to
cFOS (Oncogene, San Diego, CA) at a 1:6000 dilution. After another wash
for 1 hr in PB, the secondary antibody was added (RbAlexa Flour 594,
1:200) (Molecular Probes, Carlsbad, CA).
Lipid and Dextrin Infusion Experiments with Lymph Sampling
SD rats fasted overnight (1700–900 hrs) were cannulated with tubes in the
duodenum and lymphatic duct. After surgery, 10% glucose saline was infused
in the duodenum at 1.5 ml/hr until 1700 hrs on the surgery day. So that tubes
could be kept clear, 0.9% saline was given at 1.5 ml/hr until morning. In the
morning, fasting lymph was collected before the treatment. Two different infu-
sions were given to different groups of animals after fasting lymph was col-
lected: (1) lipid treatment, in which 2.2 ml 20% intralipid (Liposyn II, Hospra
Inc., Lake Forest, IL) plus 0.8 ml 0.9% saline was infused or (2) dextrin treat-
ment, in which 3.69 g in 10 ml PBS was infused. A bolus of either intralipid
or dextrin (3 ml) was given for each rat while 0.9% saline infusion was stopped
for 30min. After 30min, continuous infusion of 0.9% saline was given at 3ml/hr
for the rest of the 6 hr infusion, and lymph samples were collected from the
lymphatic duct at 0.5, 1, 2, 3, 4, 5, and 6 hr.
Protein Infusion Experiments with Lymph Sampling
SD rats were fasted overnight (1700–900 hrs) and were cannulated with tubes
into the duodenum and lymphatic duct the next morning. After surgery, 5%
glucose saline was infused into the rat duodenum at 3 ml/hr until 1700 hrs
that day, after which time 0.9% saline was infused at 3 ml/hr until the next
morning. At that time, fasting lymph was collected for 1 hr during the continu-
ing saline infusion. Next, a bolus of 3 ml infusion (0.8 g albumin in 3 ml) was822 Cell 135, 813–824, November 28, 2008 ª2008 Elsevier Inc.injected into the rat duodenum as the normal saline infusion was discontinued
for 30 min. After 30 min, continuous infusion of 0.9% saline was resumed at
3 ml/hr. Lymph samples were collected at the intervals indicated (Figure 1)
and centrifuged at 3000 rpm for 10 min to remove the contained cells.
NAPE Concentration in Stomach and GI Tract
SD rats (n = 8) were fasted overnight and half were refed for 90minwith high-fat
chow (59% of calories from fat, AIN-93G, Dyets, Bethlehem, PA). At this time,
all animals were sacrificed, and their GI tracts were sectioned and flash frozen
in liquid nitrogen. Tissues were then ground while frozen and NAPE was
extracted.
NAPE Secretion Experiment in DIO Rats
Two groups of rats were maintained on either regular chow or high-fat diet
(55% kcal from fat, Harlan Teklad, Madison, WI) for 35 days, at which time
theywere fasted overnight and refedwith a different high-fat chow (59%of cal-
ories from fat, AIN-93G, Dyets, Bethlehem, PA) to control for taste neophobia
effects, and plasma NAPE levels were measured throughout the re-feed via
jugular vein catheters.
ob/ob Feeding Experiments
Ad libitum-fed ob/ob mice (Jackson Labs, Bar Harbor, ME) were treated with
i.p injections of 500 mg/kg C16:0 or vehicle, and overnight food intake was
monitored.
CB1/ Feeding Experiments
CB1/mice were fasted for 24 hr and refed with regular chow after treatment
with either 500 mg/kg C16:0 NAPE or vehicle.
Radiolabeled NAPE Infusions
Rats were infused i.v. with 2.5 mCi of N-palmitoyl-1-14C phosphatidylethanol-
amine (American Radiolabeled Chemicals, St. Louis, MO). After 4 hr, brains
and hypothalami were removed, cleaned, and weighed, and radioactivity
was quantified with a scintillation counter.
Chronic NAPE Infusion Studies
Rats equipped with jugular and femoral vein catheters were placed in free-
ranging chronic infusion harnesses and coupled to infusion pumps, receiving
0.07 mg/kg-min C16:0 NAPE or vehicle (5% Tween 80, 5% propylene glycol,
90% sterile saline) continuously in the jugular vein for 5 days, while body
weight and food intake were monitored.
Lipid and Dextrin Infusion Experiments with Plasma Sampling
SD rats fasted overnight (1700–0900 hrs) were cannulated with tubes in the
jugular vein and duodenum. After surgery, 10% glucose saline was infused
in the duodenum at 1.5 ml/hr until 1700 hrs on the surgery day. So that tubes
could be kept clear, 0.9% saline was given at 1.5ml/hr until next morning. Next
morning, fasting blood (250 ml + 3 ml heparin) was collected before the treat-
ment. Two treatments were given to the animals after fasting blood was
collected: (1) lipid treatment, in which 2.2 ml 20% intralipid (Liposyn II, Hospra
Inc, Lake Forest IL) plus 0.8 ml 0.9% saline was infused, or (2) dextrin
treatment, in which 3.69 g in 10 ml PBS was infused. A bolus of either intralipid
or dextrin (3 ml) was given for each rat while 0.9% saline infusion was
stopped for 30 min. After 30 min, continuous infusion of 0.9% saline was given
at 1.5 ml/hr for the rest of the 6 hr infusion, and plasma samples were collected
at 0.5, 1, 2, 3, 4, 5, and 6 hr. A total volume of 200 ml plus 3 ml Heparin was
collected from each rat per sample. At the end of the 6 hr collection, final
plasma (3 ml) was collected from the jugular vein.
Rotarod
A group of ten mice were acclimated to the experimental device for 30 min at
2 rpm. Upon completion, all animals were again placed on the rotarod, which
was then accelerated by 0.01 rpm/s until all had fallen from the rod. On the test
day 3 days later, half of the mice were injected with 1000 mg/kg C16:0 NAPE
and the other half with a lipid control 1 hr prior to the experiment. The rotarod
test was then repeated with the same accelerating program, and the time at
which each animal fell from the rod was recorded. This test was repeated five
times.
Statistics
All data are expressed as mean ± SEM. Data were analyzed with unpaired
t tests, paired t tests, a Wilcoxon signed rank test, repeated-measures two-
way ANOVA with Bonferroni post-testing, and a one-way ANOVA followed
by a Neuman-Keuls multiple comparison test when appropriate with
GraphPad Prism (San Diego, CA).
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and four
figures and can be found with this article online at http://www.cell.com/
supplemental/S0092-8674(08)01380-9.
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